
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Some clinicians find case studies invaluable in their diagnostic arsenal. Do you? Let us know in our poll.
Do you find case studies useful? Some clinicians find them invaluable, as suggested in a classic column written by Jerry Lewis, MD, titled




